Frazier Life Sciences Management
TVTX icon

Frazier Life Sciences Management’s Travere Therapeutics TVTX Stock Holding History

Frazier Life Sciences Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-241,592
Closed -$9.23M – 43
2025
Q4 		$9.23M Sell
241,592
-150,500
-38% -$4.89M 0.25% 35
2025
Q3 		$9.37M Sell
392,092
-610,000
-61% -$11.5M 0.28% 40
2025
Q2 		$14.8M Buy
+1,002,092
New +$16.6M 0.59% 34

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Frazier Life Sciences Management's TVTX Position: Q1 2026 in Review

Frazier Life Sciences Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 241,592 shares — an estimated $9.23M sold.

Frazier Life Sciences Management first reported a position in TVTX in Q2 2025 and held it in 3 quarters. The position peaked at $14.8M in Q2 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Frazier Life Sciences Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Frazier Life Sciences Management sold 241,592 Travere Therapeutics shares in Q1 2026, an estimated $9.23M.
  • Frazier Life Sciences Management first reported a position in Travere Therapeutics in Q2 2025 and held it in 3 quarters.
  • Frazier Life Sciences Management's Travere Therapeutics position peaked at $14.8M in Q2 2025.
  • 261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.